Tamiya Yutaro, Nakai Tokiko, Suzuki Ayako, Mimaki Sachiyo, Tsuchihara Katsuya, Sato Kei, Yoh Kiyotaka, Matsumoto Shingo, Zenke Yoshitaka, Nosaki Kaname, Izumi Hiroki, Shibata Yuji, Sakai Tetsuya, Taki Tetsuro, Miyazaki Saori, Watanabe Reiko, Sakamoto Naoya, Sakashita Shingo, Kojima Motohiro, Hashimoto Naozumi, Tsuboi Masahiro, Goto Koichi, Ishii Genichiro
Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Lung Cancer. 2022 Dec;174:125-132. doi: 10.1016/j.lungcan.2022.11.001. Epub 2022 Nov 5.
Tertiary lymphoid structures (TLS) are observed in several cancers and are associated with favorable prognosis. This study aimed to examine the clinicopathological, genetic, and gene expression profiles of lung adenocarcinoma patients with TLS.
A total of 112 patients with pathological stage IB lung adenocarcinoma who underwent complete resection between 2011 and 2015 were enrolled in this study. We investigated whether TLS correlated with prognosis and programmed death-ligand 1 (PD-L1) expression. Furthermore, the correlation of TLS with tumor mutation burden (TMB) and genetic mutations was evaluated in patients for whom whole-exon sequencing data were available. In addition, using the Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) dataset, gene expression analysis according to the TLS status was performed.
Among the 112 patients, 49 were TLS-positive (TLS+). TLS+ correlated with longer recurrence-free survival (RFS) than TLS-negative cases (TLS-) (hazard ratio [HR], 0.47; 95 % confidence interval [CI]: 0.23-0.88, p = 0.02). In the multivariate analysis, TLS was a better independent prognostic factor for RFS (HR 0.37, 95 %CI 0.18-0.72, p < 0.01). PD-L1 expression was not significantly different between TLS+ and TLS- patients (p = 0.54). TMB in TLS+ was similar to that in TLS- patients (p = 0.39); however, it tended to be lower than that in TLS- especially among smokers (p = 0.07). In gene expression analysis, RNA expression of chemokines related to lymph node formation, such as CXCL13, CCL19 and CCL21, was significantly higher, and biological processes such as positive regulation of humoral immune response and regulation of antigen receptor-mediated signaling pathway were enhanced in TLS+.
TLS was a favorable prognostic factor and was not associated with PD-L1 expression in patients with lung adenocarcainoma. Moreover, gene expression analysis indicated that TLS is a site for the generation and regulation of antitumor immune responses.
在多种癌症中观察到三级淋巴结构(TLS),且其与良好的预后相关。本研究旨在探讨具有TLS的肺腺癌患者的临床病理、基因和基因表达谱。
本研究纳入了2011年至2015年间接受完整切除的112例病理分期为IB期的肺腺癌患者。我们调查了TLS是否与预后及程序性死亡配体1(PD-L1)表达相关。此外,在可获得全外显子测序数据的患者中评估了TLS与肿瘤突变负荷(TMB)及基因突变的相关性。另外,使用癌症基因组图谱肺腺癌(TCGA-LUAD)数据集,根据TLS状态进行了基因表达分析。
在112例患者中,49例为TLS阳性(TLS+)。与TLS阴性病例(TLS-)相比,TLS+与更长的无复发生存期(RFS)相关(风险比[HR],0.47;95%置信区间[CI]:0.23 - 0.88,p = 0.02)。在多变量分析中,TLS是RFS更好的独立预后因素(HR 0.37,95%CI 0.18 - 0.72,p < 0.01)。TLS+和TLS-患者之间的PD-L1表达无显著差异(p = 0.54)。TLS+中的TMB与TLS-患者相似(p = 0.39);然而,其往往低于TLS-患者,尤其是在吸烟者中(p = 0.07)。在基因表达分析中,与淋巴结形成相关的趋化因子如CXCL13、CCL19和CCL21的RNA表达显著更高,并且在TLS+中体液免疫反应的正调控和抗原受体介导的信号通路调节等生物学过程增强。
TLS是肺腺癌患者的一个良好预后因素,且与PD-L1表达无关。此外,基因表达分析表明TLS是抗肿瘤免疫反应产生和调节的场所。